Sponsor Dossier
Merck Healthcare
Sponsor Dossier for Merck Healthcare. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BAVENCIO
- Brand: CETROTIDE
- Brand: CLADRITAB
- Brand: CRINONE
- Brand: ERBITUX
- Brand: GONAL-F
- Brand: LUVERIS
- Brand: MAVENCLAD
- Device (sponsor): Empty self-injector, electronic
- Device (sponsor): Needle, injector, medication/vaccine
- Device (sponsor): Injector, medication/vaccine, needle
About
Merck Healthcare is an Australian Private Company with ABN 72 006 900 830, registered in New South Wales. The entity is active and registered for GST from 1 July 2000.
Portfolio
Merck Healthcare has 13 brands on the ARTG, of which 13 are indexable and 12 carry a Product Information document. 12 brands are PBS-listed, 9 have a PBAC outcome on record, and 5 have an AusPAR on record. Notable brands include BAVENCIO, CETROTIDE, CLADRITAB, CRINONE, ERBITUX, GONAL-F, LUVERIS, MAVENCLAD, OVIDREL, PERGOVERIS, REBIF, SAIZEN.
Therapeutic focus
— Reproductive Health: 6 brands — Neurology: 3 brands — Oncology: 3 brands — Endocrinology: 1 brand
PBS footprint
12 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest PBAC outcome is 2024-11-01, across 9 brands with a PBAC outcome on record. The latest AusPAR is 2022-09-01, across 5 brands with an AusPAR on record.